Whitehawk Therapeutics, Inc. (WHWK) – What Are Analysts Thinking About This Stock?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has been given an average rating of “Moderate Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.33.

Several equities analysts recently commented on WHWK shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Wednesday, September 2nd. Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Leerink Partners began coverage on shares of Whitehawk Therapeutics in a research report on Monday, July 13th. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, Stifel Nicolaus began coverage on shares of Whitehawk Therapeutics in a research note on Wednesday, September 30th. They set a “buy” rating and a $9.00 price objective on the stock.

Whitehawk Therapeutics Price Performance

Shares of WHWK opened at $3.13 on Monday. Whitehawk Therapeutics has a 12 month low of $1.97 and a 12 month high of $5.49. The stock’s 50-day moving average is $3.68 and its two-hundred day moving average is $3.83. The stock has a market cap of $178.44 million, a PE ratio of -2.79 and a beta of 0.99.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. On average, research analysts anticipate that Whitehawk Therapeutics will post -1.00 earnings per share for the current year.

Institutional Trading of Whitehawk Therapeutics

Several large investors have recently modified their holdings of the business. Two Sigma Securities LLC purchased a new stake in Whitehawk Therapeutics during the 2nd quarter worth approximately $46,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Whitehawk Therapeutics during the 1st quarter valued at approximately $40,000. Deutsche Bank AG purchased a new position in shares of Whitehawk Therapeutics during the 2nd quarter valued at approximately $145,000. Bank of America Corp DE acquired a new stake in shares of Whitehawk Therapeutics during the second quarter worth approximately $159,000. Finally, Eversept Partners LP increased its stake in shares of Whitehawk Therapeutics by 17.9% in the first quarter. Eversept Partners LP now owns 306,800 shares of the company’s stock worth $1,058,000 after buying an additional 46,541 shares during the last quarter. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development.

Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.

Publicly available information about the company’s specific pipeline, operating geographies and leadership is limited.